Abstract
Breast cancer is the most common type of cancer among women in Denmark. In 15% of the patients with metastatic breast cancer (mBC) an overexpression of the HER2 protein on the tumour cells, amplification of the HER2-gene or both are present. HER2-positive mBC is associated with poor disease prognosis. The discovery of HER2 led to the development of HER2-targeting monoclonal antibodies significantly improving survival for patients with HER2-positive mBC as summarised in this review. The future brings even more HER2-targeting drugs, which further can contribute to the palliative treatment of HER2-postive mBC patients.
| Bidragets oversatte titel | Targeted treatment of HER2-positive metastatic breast cancer improves prognosis significantly |
|---|---|
| Originalsprog | Dansk |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 183 |
| Udgave nummer | 26 |
| Sider (fra-til) | V12200938 |
| ISSN | 0041-5782 |
| Status | Udgivet - 28 jun. 2021 |
| Udgivet eksternt | Ja |
Emneord
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms/drug therapy
- Female
- Humans
- Prognosis
- Receptor, ErbB-2/therapeutic use